Background
Phase III, open-label, randomized, parallel-group, superiority trial. 226 patients with newly diagnosed, advanced, higher-grade well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET): Grade 2 Ki67 ≥10–20% or Grade 3 Ki67 >20–55%. All target lesions required somatostatin receptor (SSTR) positivity on functional imaging. Randomized 2:1 (PRRT:control) across 45 centers in 9 countries, stratified by grade (G2 vs G3) and primary origin (pancreas vs other). This was the first randomized trial of PRRT in first-line treatment of higher-grade GEP-NET.
Interventions and follow up
Arm A: [177Lu]Lu-DOTATATE (Lutathera) 7.4 GBq IV every 8 weeks ×4 cycles + octreotide LAR 30 mg IM q4wk → maintenance octreotide LAR 30 mg IM q4wk (n=151)
Arm B: High-dose octreotide LAR 60 mg IM q4wk (n=75)
Primary endpoint: PFS by blinded independent central radiology (RECIST 1.1)
Median follow-up: Analysis at 101 PFS events (final PFS analysis)
Arm B: High-dose octreotide LAR 60 mg IM q4wk (n=75)
Primary endpoint: PFS by blinded independent central radiology (RECIST 1.1)
Median follow-up: Analysis at 101 PFS events (final PFS analysis)
Results
mPFS (Arm A vs B): 22.8 months (95% CI 19.4–NE) vs 8.5 months (95% CI 7.7–13.8)
HR: 0.276 (95% CI 0.182–0.418), P<.0001
OS: Immature at primary analysis; no significant difference reported
HR: 0.276 (95% CI 0.182–0.418), P<.0001
OS: Immature at primary analysis; no significant difference reported
Adverse events
Overall: Any-grade AEs in 93% (Lu-DOTATATE) vs 95% (control); no study-drug-related deaths.
Hematologic: Grade 3–4 thrombocytopenia and neutropenia, consistent with the known PRRT safety profile.
Renal: No grade 4 renal toxicity signals; radiation nephropathy risk monitored via renal dosimetry.
Hematologic: Grade 3–4 thrombocytopenia and neutropenia, consistent with the known PRRT safety profile.
Renal: No grade 4 renal toxicity signals; radiation nephropathy risk monitored via renal dosimetry.
Conclusions
First-line [177Lu]Lu-DOTATATE plus octreotide LAR significantly prolonged PFS by a median of 14 months versus high-dose octreotide in higher-grade G2–G3 SSTR-positive GEP-NET (HR 0.276, P<.0001). NETTER-2 establishes Lu-DOTATATE as a new first-line standard of care in this molecularly selected, higher-grade population previously reliant on chemotherapy.
Key Limitations
Key Limitations: Open-label design introduces performance and detection bias. The comparator arm (high-dose octreotide 60 mg) is not a guideline-endorsed standard, which inflates the apparent magnitude of benefit. OS data immature at primary analysis. The strict SSTR-positivity requirement (all target lesions) is more stringent than NETTER-1 criteria, limiting generalizability. Ki67 >55% grade 3 NET excluded — the highest-risk group with the least to gain from PRRT. Long-term renal and hematologic toxicity requires extended follow-up.
Clinical Context
NETTER-1 established Lu-DOTATATE for second-line midgut NET (vs high-dose octreotide). NETTER-2 extends this indication to first-line treatment of higher-grade G2–G3 GEP-NET, a population previously managed with chemotherapy (streptozotocin-based for pNET, or platinum-based for poorly differentiated NEC). FDA approved Lu-DOTATATE for higher-grade GEP-NET in 2024 based on NETTER-2. ENETS and NANETS guidelines now list first-line PRRT as an option in SSTR-high G2–G3 GEP-NET. Access to qualified nuclear medicine facilities with dosimetry capability remains a practical barrier.
References
References: Singh S et al, Lancet 2024 (NETTER-2)